Status:
COMPLETED
Tailored Therapy for Clarithromycin-Resistant H. Pylori
Lead Sponsor:
Kangdong Sacred Heart Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
19-85 years
Phase:
NA
Brief Summary
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recent...
Eligibility Criteria
Inclusion
- peptic ulcer disease
- H. pylori gastritis
- low grade MALT lymphoma
Exclusion
- history of gastric cancer surgery
- severe comorbidity (ESRD, LC)
- hypersensitivity to drug
- pregnancy
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
782 Patients enrolled
Trial Details
Trial ID
NCT03431688
Start Date
October 1 2018
End Date
December 30 2020
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kangdong Sacred Heart Hospital
Seoul, South Korea, 134-701